One stone with two birds: Phytic acid-capped platinum nanoparticles for targeted combination therapy of bone tumors

• Published in: Biomaterials 2019-02, Vol.194, p.130-138
• Main Authors: Zhou, Zhengjie, Fan, Tianqi, Yan, Yang, Zhang, Song, Zhou, Yi, Deng, Hanbin, Cai, Xiaopan, Xiao, Jianru, Song, Dianwen, Zhang, Qiang, Cheng, Yiyun
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents - therapeutic use; Bone Neoplasms - pathology; Bone Neoplasms - therapy; Bone targeting; Cell Line, Tumor; Combination therapy; Combined Modality Therapy - methods; Drug Delivery Systems - methods; Humans; Hyperthermia, Induced - methods; Inherent anticancer activity; Male; Mice; Mice, Inbred BALB C; Nanoparticles - therapeutic use; NIH 3T3 Cells; Photothermal therapy; Phytic acid; Phytic Acid - therapeutic use; Platinum - therapeutic use
• ISSN: 0142-9612; 1878-5905
• DOI: 10.1016/j.biomaterials.2018.12.024

Targeted drug delivery to malignant bone lesions remains a challenging task in the treatment of bone tumors. In this article, we reported a naturally occurring phytic acid (PA) with both bone-targeting capability and anticancer activity. The PA-capped platinum nanoparticles showed high affinity to hydroxyapatite in vitro and in vivo, and maintained both the inherent anticancer ability of PA and photothermal effect of platinum nanoparticles. PA-capped nanoparticles displayed a 4-fold higher accumulation in the osteolytic lesions than sodium citrate-templated ones, and efficiently inhibited bone tumor growth and the tumor associated-osteolysis upon exposure to a near-infrared light. This study provides a novel and efficient strategy to prepare bone-targeted nanoparticles with inherent anticancer activity for combination therapy of malignant bone tumors.